ArticleFrontiers in endocrinology2025
Hashimoto's thyroiditis and nanophthalmos in Gabriele-de Vries syndrome: a case report.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gabriele-de Vries syndrome (GADEVS, OMIM 617557) is a rare autosomal dominant disorder caused by pathogenic variants in the YY1 gene. This report describes a case of GADEVS with concurrent Hashimoto's thyroiditis (HT) and nanophthalmos, a previously unreported association. Case presentation: We present a case of a 9-year-5-month-old girl who was admitted to the Pediatric Endocrinology Outpatient Clinic due to an asymptomatic neck lump and multiple malformations.Physical examination revealed mild facial dysmorphism, strabismus, an enlarged thyroid gland, and elongated fingers. Laboratory findings showed: thyroid-stimulating hormone (TSH): 68.98 μIU/mL (reference range: 0.27-4.2 μIU/mL); free thyroxine (FT4): 7.51 pmol/L (reference range: 12-22 pmol/L); anti-thyroid peroxidase antibodies:>600IU/mL (reference range: 0-34 IU/mL). Ultrasonography revealed that the left thyroid lobe measured 38 × 11 × 12 mm, the right lobe 39 × 11 × 13 mm, and the isthmus had a thickness of 3.2 mm. Ocular axial measurements confirmed nanophthalmos, and cognitive assessments indicated mild cognitive impairment. Whole-exome sequencing identified a novel heterozygous YY1 mutation (c.385del), resulting in a frameshift variant (p.D129Ifs*127). Levothyroxine replacement therapy successfully corrected the hypothyroidism. After three years of treatment, the patient exhibited: a height increase of 20.3 cm, and an improvement in height percentile from the 10th to the 25th percentile. Conclusion: Hypothyroidism has been reported in four previous cases (12%) of GADEVS, but autoimmune thyroiditis has not been documented. This suggests that thyroid dysfunction in GADEVS may be associated with underlying immune dysfunction and warrants further evaluation. In the present case, we identified a mutation in the YY1 gene, which is associated with nanophthalmos and may underlie the ocular abnormalities such as strabismus and hyperopia. Clinically, children with GADEVS should undergo comprehensive assessments of thyroid function, thyroid autoantibodies, and ophthalmologic status to facilitate early diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.